<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092439</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC2019024</org_study_id>
    <nct_id>NCT04092439</nct_id>
  </id_info>
  <brief_title>The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function</brief_title>
  <acronym>WMJ</acronym>
  <official_title>The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if watermelon juice supplementation improves vascular
      dysfunction experience during hyperglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to determine the potential for watermelon juice to
      attenuate the reduction postprandial endothelial function and skeletal muscle microvascular
      blood flow (MVBF) experienced during hyperglycemia.

      We will attempt to answer the following hypotheses:

      Hypothesis 1: Watermelon juice supplementation will attenuate the reduction in endothelial
      dysfunction and microvascular blood flow during an oral glucose challenge.

      Hypothesis 2: Watermelon juice will increase L-arginine bioavailability during hyperglycemia
      and correlate with improved vascular response.

      Exploratory Aim: The postprandial period is defined by increased sympathetic nervous system
      activity (vasoconstriction) and NO• mediated vasodilation. Heart rate variability (HRV) is a
      measurement of the balance of parasympathetic to sympathetic activity. We will measure HRV
      during the oral glucose challenge to interrogate the possibility that watermelon juice can
      modulate the balance of blood vessel constriction and relaxation during an oral glucose

      Procedures Involved

      There will be 1 screening visit, and 2 outpatient visits. Participants will consume
      watermelon juice or placebo for 2 weeks. The washout period will last 2 weeks prior to the
      cross-over to the opposite condition. Participants visits will be conducted at the Vascular
      and Resting Metabolism Lab located in the department of kinesiology at LSU.

      Screening Visit

      Participants will undergo consenting and fasting blood draws to measure glucose, lipids, and
      CBC. Vital signs (blood pressure, body weight, body composition (DXA), heart rate, etc) will
      be measured. For DXA procedure participants will undergo a whole body scan lasting
      approximately 10 minutes. Participants will remove all metal objects from their body and lie
      down on the table. The legs will be secured together using two Velcro straps. The participant
      will be instructed to remain completely still during the scan. Randomization will be
      performed to allocate the study participant for their initial group assignment to either the
      watermelon juice group or placebo. The initial six participants will be assigned treatment A
      for phase 1 and treatment B for phase 2, thereafter the following 6 will be assigned
      treatment B first then treatment A. The remaining participant will be randomly assigned
      either treatment A or B in a counterbalanced fashion.

      Daily Juice Drop-in visits

      Since the required supplementation duration is 14 days participants will be provided with 2
      days (Saturday and Sunday) worth of watermelon juice or placebo to account for days when the
      LSU AG Center will not be open. To allow for scheduling conflicts and unforeseen
      circumstances a 3 day period of supplementation less then or greater than the 14 periods will
      be permitted. Participants will also be provided with juice or placebo for anticipated
      instances where they cannot be on campus. In order to monitor compliance participants will be
      asked return the juice container for the days where juice was consumed off premises.

      Visit 2 and 3: Oral Glucose Challenge - Postprandial FMD and MVBF

      Participants will arrive in morning at 6:00am fasted for 10-hours. Body composition will be
      measured by DXA. Next, participants will rest for 30 minutes in the supine positing while
      wearing a heart rate monitor (Zephyr, Bioharness) to measure heart rate and heart rate
      variability. Resting metabolic rate will be measured via indirect calorimetry for 20 minutes.
      Then fasting measures of blood glucose, FMD (ultrasound) and MVBF (near-infrared
      spectroscopy) will be taken followed by ingestion of 75 g of glucose (glucola). An IV line
      will be placed in the participants arm vein for blood draw purposes and will remain there
      throughout the testing. A blood sample will be drawn, and then the participant will drink a
      sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after
      you consume the drink. Each blood sample will be about 1 tablespoon. (6 tablespoons total for
      the test). During the IV procedure, a small amount of the participant's own blood (less than
      1 teaspoon) will immediately be returned into your vein through the IV after each specimen is
      collected. Blood will be drawn at minute 15, 30, 60, 90, 120 minutes. Postprandial
      measurements of FMD and MVBF will be taken at 30, 60, 90, and 120 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>Two weeks</time_frame>
    <description>Flow mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Blood Flow</measure>
    <time_frame>Two weeks</time_frame>
    <description>microvascular blood flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Watermelon juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% watermelon juice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fructose matched control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Watermelon Juice</intervention_name>
    <description>100% Watermelon Juice</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Watermelon juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable and willing to give written informed consent and understand inclusion and
             exclusion criteria.

          2. 18-40 years of age

          3. BMI between 18-29.9 kg/m2

          4. Willing to allow researchers to draw blood and conduct imaging (DXA) for research
             purposes.

        Exclusion Criteria:

          1. Evidence or self-reported history of type 1 or 2 diabetes mellitus

          2. Self-reported family history of type 2 diabetes (first degree relative with type 2
             diabetes)

          3. Evidence or self-report history of deep vein thrombosis, pulmonary embolism,
             cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease

          4. Allergy to watermelon

          5. Use of medication known to influence study outcomes, such as:

               1. Insulin

               2. Anti-diabetics (metformin)

               3. Corticosteroids

               4. Beta-blockers

               5. Anti-coagulates

          6. Use of supplements known to influence study outcomes, such as;

               1. Beta-alanine

               2. L-arginine

               3. L-citrulline

          7. Active smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy D Allerton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baena-Díez JM, Peñafiel J, Subirana I, Ramos R, Elosua R, Marín-Ibañez A, Guembe MJ, Rigo F, Tormo-Díaz MJ, Moreno-Iribas C, Cabré JJ, Segura A, García-Lareo M, Gómez de la Cámara A, Lapetra J, Quesada M, Marrugat J, Medrano MJ, Berjón J, Frontera G, Gavrila D, Barricarte A, Basora J, García JM, Pavone NC, Lora-Pablos D, Mayoral E, Franch J, Mata M, Castell C, Frances A, Grau M; FRESCO Investigators. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. Diabetes Care. 2016 Nov;39(11):1987-1995. Epub 2016 Aug 4.</citation>
    <PMID>27493134</PMID>
  </reference>
  <reference>
    <citation>Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9. doi: 10.1056/NEJMoa1000367. Erratum in: N Engl J Med. 2011 Sep 1;365(9):869.</citation>
    <PMID>21121834</PMID>
  </reference>
  <reference>
    <citation>Avogaro A. Postprandial glucose: marker or risk factor? Diabetes Care. 2011 Oct;34(10):2333-5. doi: 10.2337/dc11-1442.</citation>
    <PMID>21949226</PMID>
  </reference>
  <reference>
    <citation>Enkhmaa B, Ozturk Z, Anuurad E, Berglund L. Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus. Curr Diab Rep. 2010 Feb;10(1):61-9. doi: 10.1007/s11892-009-0088-4.</citation>
    <PMID>20425069</PMID>
  </reference>
  <reference>
    <citation>Keske MA, Premilovac D, Bradley EA, Dwyer RM, Richards SM, Rattigan S. Muscle microvascular blood flow responses in insulin resistance and ageing. J Physiol. 2016 Apr 15;594(8):2223-31. doi: 10.1113/jphysiol.2014.283549. Epub 2015 Jan 12. Review.</citation>
    <PMID>25581640</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E123-9.</citation>
    <PMID>12791603</PMID>
  </reference>
  <reference>
    <citation>Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996 Mar 1;27(3):567-74.</citation>
    <PMID>8606266</PMID>
  </reference>
  <reference>
    <citation>Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993 Dec;88(6):2510-6.</citation>
    <PMID>8080489</PMID>
  </reference>
  <reference>
    <citation>Tessari P, Cecchet D, Cosma A, Vettore M, Coracina A, Millioni R, Iori E, Puricelli L, Avogaro A, Vedovato M. Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. Diabetes. 2010 Sep;59(9):2152-9. doi: 10.2337/db09-1772. Epub 2010 May 18.</citation>
    <PMID>20484137</PMID>
  </reference>
  <reference>
    <citation>Förstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem. 2006 Dec;387(12):1521-33. Review.</citation>
    <PMID>17132097</PMID>
  </reference>
  <reference>
    <citation>Deveaux A, Pham I, West SG, André E, Lantoine-Adam F, Bunouf P, Sadi S, Hermier D, Mathé V, Fouillet H, Huneau JF, Benamouzig R, Mariotti F. l-Arginine Supplementation Alleviates Postprandial Endothelial Dysfunction When Baseline Fasting Plasma Arginine Concentration Is Low: A Randomized Controlled Trial in Healthy Overweight Adults with Cardiometabolic Risk Factors. J Nutr. 2016 Jul;146(7):1330-40. doi: 10.3945/jn.115.227959. Epub 2016 Jun 8.</citation>
    <PMID>27281800</PMID>
  </reference>
  <reference>
    <citation>Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006 Jan 4;295(1):58-64.</citation>
    <PMID>16391217</PMID>
  </reference>
  <reference>
    <citation>Agarwal U, Didelija IC, Yuan Y, Wang X, Marini JC. Supplemental Citrulline Is More Efficient Than Arginine in Increasing Systemic Arginine Availability in Mice. J Nutr. 2017 Apr;147(4):596-602. doi: 10.3945/jn.116.240382. Epub 2017 Feb 8.</citation>
    <PMID>28179487</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Timothy Allerton, PhD</investigator_full_name>
    <investigator_title>Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

